SCYNEXIS has a proven track record of success in identifying chemical series with anti-parasitic properties that are currently being evaluated for endo-and ectoparasitic activity for Animal Health indications.  The Integrated Parasitology Animal Health platform allows for the rapid evaluation of compounds against a broad spectrum of parasite species relevant to key animal health markets.  The team has developed screening paradigms to drive discovery programs forward is an efficient manner.

The SCYNEXIS screening paradigms allow for the screening of large or focused compound collections against various parasite species. Large compound collections, between 100 and 100,000 compounds, are initially tested in primary screens against three species relevant to helminths, arthropods and protozoans. Compounds active from these initial screens or focused compound collections are tested directly against target parasite species. Prioritized compounds are then progressed to in vivo studies.

SCYNEXIS multidisciplinary teams consisting of biology, chemistry, DMPK and analytical chemists, work together to optimize chemical series for desired properties aligned with our partners target product profiles. SCYNEXIS has delivered to our partners with several compounds currently in development.

We would be happy to discuss our technical expertise and business model with you in more detail to determine opportunities to work with your organization.